OBJECTIVES: : To test if circulating forms of the soluble urokinase-type plasminogen activator receptor (suPAR) are potential biomarkers of plaque vulnerability. DESIGN AND METHODS: : Plasma concentrations of suPAR(I-III), suPAR(II-III) and uPAR(I) were measured by time-resolved fluorescence immunoassays in Caucasian patients operated for symptomatic carotid atherosclerosis (n=255). Local suPAR release from plaques into the circulation was assessed in plasma passing retrogradely over the plaque in the carotid artery, collected during surgery (n=7). RESULTS: : The suPAR(I-III) (P=0.03) and suPAR(II-III) (P=0.006) concentrations were higher after ischemic strokes and transient ischemic attacks, i.e., clinical subgroups associated with poorer prognosis and a less stable plaque phenotype, than after amaurosis fugax. Slightly elevated suPAR(I-III) levels were found in plasma from the carotid lesion. However, refuting the hypothesis, the concentrations of the suPAR forms were not higher in patients with short intervals between clinical event and blood sampling compared with those with long intervals. Age, inflammatory markers and diabetes were confounding factors independently associated with suPAR forms. CONCLUSION: : Circulating suPAR forms are probably not useful biomarkers of atherosclerotic plaque vulnerability. Copyright 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: : To test if circulating forms of the soluble urokinase-type plasminogen activator receptor (suPAR) are potential biomarkers of plaque vulnerability. DESIGN AND METHODS: : Plasma concentrations of suPAR(I-III), suPAR(II-III) and uPAR(I) were measured by time-resolved fluorescence immunoassays in Caucasian patients operated for symptomatic carotid atherosclerosis (n=255). Local suPAR release from plaques into the circulation was assessed in plasma passing retrogradely over the plaque in the carotid artery, collected during surgery (n=7). RESULTS: : The suPAR(I-III) (P=0.03) and suPAR(II-III) (P=0.006) concentrations were higher after ischemic strokes and transient ischemic attacks, i.e., clinical subgroups associated with poorer prognosis and a less stable plaque phenotype, than after amaurosis fugax. Slightly elevated suPAR(I-III) levels were found in plasma from the carotid lesion. However, refuting the hypothesis, the concentrations of the suPAR forms were not higher in patients with short intervals between clinical event and blood sampling compared with those with long intervals. Age, inflammatory markers and diabetes were confounding factors independently associated with suPAR forms. CONCLUSION: : Circulating suPAR forms are probably not useful biomarkers of atherosclerotic plaque vulnerability. Copyright 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Authors: Aizhen Yang; Jihong Dai; Zhanli Xie; Robert W Colman; Qingyu Wu; Raymond B Birge; Yi Wu Journal: J Immunol Date: 2014-03-31 Impact factor: 5.422
Authors: Paulo Rabna; Andreas Andersen; Christian Wejse; Ines Oliveira; Victor Francisco Gomes; Maya Bonde Haaland; Peter Aaby; Jesper Eugen-Olsen Journal: Inflammation Date: 2010-12 Impact factor: 4.092
Authors: Juha Onatsu; Mikko Taina; Pirjo Mustonen; Marja Hedman; Antti Muuronen; Otso Arponen; Miika Korhonen; Pekka Jäkälä; Ritva Vanninen; Kari Pulkki Journal: In Vivo Date: 2017 May-Jun Impact factor: 2.155
Authors: Paraskevi Briassouli; Marc K Halushka; Joanne H Reed; Yair Molad; Karen Fox-Talbot; Lucas Buyon; Edwin Guzman; Achiau Ludomirsky; Robert M Clancy; Jill P Buyon Journal: Rheumatology (Oxford) Date: 2013-04-18 Impact factor: 7.580
Authors: Enrico Ammirati; Francesco Moroni; Giuseppe Danilo Norata; Marco Magnoni; Paolo G Camici Journal: Mediators Inflamm Date: 2015-04-16 Impact factor: 4.711
Authors: Heikki Kiiski; Ville Jalkanen; Marika Ala-Peijari; Mari Hämäläinen; Eeva Moilanen; Jukka Peltola; Jyrki Tenhunen Journal: Front Neurol Date: 2017-04-18 Impact factor: 4.003
Authors: Line H Dohn; Peter Thind; Lisbeth Salling; Henriette Lindberg; Sofie Oersted; Ib J Christensen; Ole D Laerum; Martin Illemann; Hans von der Maase; Gunilla Høyer-Hansen; Helle Pappot Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639